Back to Dashboard

NEOG

active

Neogen Corporation

Gap
+5.4%
HealthcareEPS Oct 6, 2026

Price Chart

Range
NEOG · DailyEMA 12EMA 26EMA 50EMA 200

Gap Information

Current
—
Prev Close
$11.96
Open
$12.61
Gap %
+5.4%
Close
$12.07
Day High
$12.92
Day Low
$11.66
Volume
1.34M
Vol vs 50d Avg
0.4x
Significant Volume

Score Analysis

Model 1: Rerate Score

Composite48/ 100
Gap Quality (30%)39
Volume Quality (25%)25
Earnings Quality (25%)77
Technical Context (20%)55

Model 2: Trade Probability

P(win)47%20d horizon
Tier:LOW
Expected Return+0.7%
Trained on 240 trades across 142 tickers (2y backtest). Volume sweet spot (1-2×) and tight ATR risk are strongest predictors.

Model 3: Tail Probability (Runner)

P(runner)24.1%60d ≥ +20%
Tier:WEAK
Frozen walk-forward logistic model (OOS AUC 0.64–0.68). Ranks the fat tail — many small losses, a few huge 60-day runners. STRONG tier historically hit ~44% (vs 25% base). A ranking tool, not a certainty.
Forward P/E
19.50
PEG Ratio
2.00
FCF Trend
stable
Buyback
No

AI Thesis

Neogen is a classic post-merger turnaround story that has badly tested investor patience since acquiring 3M's food safety business in late 2022. The deal transformed Neogen into a food safety diagnostics leader, but integration missteps, gross margin degradation, sluggish low-single-digit organic growth, and a leveraged balance sheet crushed the stock from its post-merger highs. A 50% EPS beat in this context matters far less for the absolute dollar figure (the earnings base is small) and far more as tangible evidence that the company's business transformation program — targeting tens of millions in cost savings and gross margin recovery toward pre-merger levels — is finally flowing through to the bottom line. When a stock is priced for continued execution failure, positive operating leverage surprises force skeptics to re-run their models, which is exactly the setup that produces multiple re-rating rather than just an earnings-driven pop. Structurally, the bull case for a durable rerating rests on margin normalization: every 100bp of gross margin recapture from the 3M integration drops disproportionately to operating income given depressed margins, while a new leadership team and portfolio pruning (including divesting non-core assets) improve credibility with the Street. Food safety testing demand is regulatory-driven, recurring, and secularly growing, giving the revenue floor stability while the self-help story provides the earnings delta. The gap also repositioned the stock above the 50-day SMA with the 200-day at $10.07 acting as a rising floor — technically, the chart is shifting from persistent downtrend to potential base-building. The key caveat is conviction: this gap came on just 0.42x average volume, meaning it occurred on thin participation rather than heavy institutional accumulation. That materially raises the odds of a fade or fill unless follow-through buying and a guidance raise confirm the beat was operational improvement rather than easy comparisons or one-off cost timing. Wall Street will want proof that margin expansion is sustainable and organic growth is inflecting before paying a premium multiple again.

Analyzed by rerate-v2+glm-5.2 · Oct 7, 2026

Catalysts

  • Business transformation cost-savings program ramping ahead of schedule, driving the outsized EPS beat
  • Gross margin recovery toward pre-3M-merger normalized levels — each 100bp of recapture is high-operating-leverage upside
  • Deleveraging of the post-merger balance sheet, improving financial flexibility and interest expense trajectory
  • Portfolio simplification via divestitures of non-core, lower-margin businesses
  • New management team rebuilding credibility after post-merger execution failures
  • Recurring, regulation-driven food safety and animal safety testing demand providing revenue stability
  • Technical reclaim of the 50-day SMA with the 200-day rising at $10.07 as support — base-building pattern after a prolonged drawdown

Risks

  • Gap occurred on only 0.42x average volume — weak institutional conviction and elevated risk the gap fades or fills without follow-through
  • Small EPS base makes a 50% beat optically impressive but economically modest; revenue surprise and guidance are unknown
  • Organic growth has been stuck in low single digits, which caps multiple expansion if the beat was all cost-cut rather than demand
  • Integration execution risk from the 3M food safety merger remains unresolved until margins stabilize for multiple quarters
  • Elevated leverage from the merger limits capital returns and amplifies risk if cash generation disappoints
  • Tariff and FX exposure on international sales could pressure the margin recovery path
  • Stock sits right at the 50-day SMA ($12.08) — overhead resistance until reclaimed decisively

Technical Setup

Setup Type
Day-1 Play
Entry Price
$11.68
Stop Loss
$11.37
vs SMA 200
Above
SMA 50
$12.08
SMA 200
$10.07
EMA 10
$12.58

Forward Returns

Forward returns (1d, 5d, 20d, 60d) are tracked after the gap-up resolves. Check back for updated performance metrics.